Publikationen in Zusammenarbeit mit Forschern von University of Edinburgh (5)

2024

  1. The SRC family kinase inhibitor NXP900 demonstrates potent antitumor activity in squamous cell carcinomas

    Journal of Biological Chemistry, Vol. 300, Núm. 9

2023

  1. Lipid-core nanoparticles: Classification, preparation methods, routes of administration and recent advances in cancer treatment

    Advances in Colloid and Interface Science, Vol. 314

  2. Maslinic acid solid lipid nanoparticles as hydrophobic anticancer drug carriers: Formulation, in vitro activity and in vivo biodistribution

    Biomedicine and Pharmacotherapy, Vol. 163

2022

  1. EZH2 endorses cell plasticity to non-small cell lung cancer cells facilitating mesenchymal to epithelial transition and tumour colonization

    Oncogene, Vol. 41, Núm. 28, pp. 3611-3624

  2. Screening of NXP900 and dasatinib across 121 cancer cell lines identifies differences in their antiproliferative activity profiles

    European Journal of Cancer, Vol. 174, pp. S113